Literature DB >> 23752410

SGLT2 inhibitors enter crowded diabetes space.

Aaron Bouchie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23752410     DOI： 10.1038/nbt0613-469

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  SGLT2 inhibitors race to enter type-2 diabetes market.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2012-10       Impact factor: 54.908
  1 in total
  5 in total

1.  Real world points to SGLT-2 blockers advantage.

Authors: 
Journal:  Nat Biotechnol       Date:  2017-04-11       Impact factor: 54.908

2.  Genomics pioneer gets its first drug.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2017-05-09       Impact factor: 54.908

3.  Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.

Authors:  Seok Joon Shin; Sungjin Chung; Soo Jung Kim; Eun-Mi Lee; Young-Hye Yoo; Ji-Won Kim; Yu-Bae Ahn; Eun-Sook Kim; Sung-Dae Moon; Myung-Jun Kim; Seung-Hyun Ko
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

Review 4.  Bioisosteres of Carbohydrate Functional Groups in Glycomimetic Design.

Authors:  Rachel Hevey
Journal:  Biomimetics (Basel)       Date:  2019-07-28

5.  Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.

Authors:  Naoto Terami; Daisuke Ogawa; Hiromi Tachibana; Takashi Hatanaka; Jun Wada; Atsuko Nakatsuka; Jun Eguchi; Chikage Sato Horiguchi; Naoko Nishii; Hiroshi Yamada; Kohji Takei; Hirofumi Makino
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.